Michael McCormack, MD
Medical Oncology · Hagerstown, MDNPI 1821018821
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,665 of the $2,195 with a category attached, or 75.9%. AstraZeneca accounts for 81.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,964 and has fallen 94.1% since, to $116 in 2025. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 11 payments — averaging $199.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$218
- E.r. Squibb & Sons, L.L.C.$117
- Takeda Pharmaceuticals U.S.A., Inc.$33
- Fortovia Therapeutics, Inc.$12
- Gilead$12
- plus $5 from 1 others
Across 19 payments — averaging $5588.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$83K
- Amgen$18K
- Pfizer$6K
What the payments were for
- Consulting fees$1,66576%
- Food & beverage$48022%
- Education$502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $1,797 |
| AbbVie | 3 | $218 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Fortovia Therapeutics, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,195 in reported general payments places this provider in the 40th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Hagerstown
- Mario EisenbergerBaltimore$2.9M
- Adrian SenderowiczBethesda$1.6M
- Mohit NarangOwing Mills$1.3M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.